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Abstract
Background: We investigated the immune response to serogroup 6 with the opsonophagocytic killing assay
(OPKA) in children aged 12–23 months of age after immunization with the 7-valent pneumococcal conjugate
vaccine (PCV7) containing serotype 6B.
Methods: Blood samples were obtained from 59 children who had blood sampling for medical examination.
Immunization status against PCV7 was confirmed by immunization records and samples were categorized
according to immunization status into a booster, primary, or control group. The OPKA was performed for serotypes
6A, 6B, 6C, and 6D.
Results: Subjects with no previous PCV7 immunization history showed opsonic activity for serogroup 6 in 5-30%
(according to serotype). In subjects vaccinated with a 3-dose primary series, 81% showed opsonic activity for
serotypes 6B and 6D, and 29% showed opsonic activity for serotypes 6A and 6C. Among subjects vaccinated with a
booster dose, all subjects had opsonic activity against serotype 6B. Subjects in the booster group with opsonic
activity against serotypes 6A, 6C, and 6D were 100%, 78%, and 89%, respectively.
Conclusions: In subjects aged 12–23 months, an immune response is elicited after a primary series of
immunizations with PCV7 for serotypes 6B and 6D, and a booster dose enhances a cross reactive immune response
against serotypes 6A, 6C and 6D.
Keywords: Streptococcus pneumoniae, Heptavalent pneumococcal conjugate vaccine, Pneumococcal polysaccharide
type 6
Background
Streptococcus pneumoniae is a major cause of meningitis,
pneumonia, and bacteremia in children and adults through-
out the world. It is also a major cause of acute otitis media
and sinusitis. With the introduction of the 7-valent
pneumococcal conjugate vaccine (PCV7, Prevenar®, Pfizer
Inc, Philadelphia, PA), a substantial decrease in invasive
pneumococcal disease (IPD) due to serotypes included in
the vaccine was seen among children and adults [1] since
protection against S. pneumoniae is a serotype-specific im-
mune response [2].
Up to several years ago, only serotypes 6A and 6B were
grouped into serogroup 6 due to similarity in both chemical
structure and serological properties of their capsular poly-
saccharides. Following the recent discovery of two new
members, serogroup 6 now consists of 4 serotypes: 6A, 6B,
6C, and 6D [3,4]. Although S. pneumoniae serotype 6C is
quite prevalent throughout the world, serotype 6D isolates
are relatively rare in many countries [5-14]. For instance,
the US CDC identified only two 6D isolates in its extensive
multi-year surveys [15]. This rare finding of 6D in the US
may be due to adequate cross-protection against 6D by
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PCV7, which contains serotype 6B PS that is similar to 6D
PS in structure.
In contrast to the US, several epidemiologic studies in
Korea reported high prevalence of serotype 6D, which
accounts for up to 5-10% of serogroup 6 isolates [16,17].
They are found both among adults and children. This
unusually high prevalence of 6D is unexpected since
PCV7 is also widely used in Korea. Therefore it is pos-
sible that PCV7 does not elicit cross-protective anti-
bodies against serotype 6D among Korean children. To
investigate this possibility, we examined the immune re-
sponse to serotypes 6A, 6C, and 6D, as well as 6B, with
the opsonophagocytic killing assay (OPKA) in children
aged 12–23 months of age after vaccination with PCV7.
Methods
Subjects
Subjects included in this study were children aged 12–23
months who had blood sampling for medical examination.
Blood samples were obtained after informed consent.
Immunization status against PCV7 was confirmed by
immunization records and samples were categorized
according to immunization status. Subjects with 3 primary
doses and 1 booster dose of PCV7 were assigned to the
booster group, subjects with 3 primary doses before 12
months of age were assigned to the primary group, and
subjects with no vaccination history of PCV7 were assigned
to the control group. Samples from 45 subjects who visited
Kangnam CHA Medical Center from September to De-
cember 2006 have been described previously [18]. Serum
samples from 14 subjects were additionally collected at
Ewha Womans University Mokdong Hospital from No-
vember 2007 to February 2008. Children with underlying
immunodeficiency disorders or a history of blood transfu-
sion, immunoglobulin, or systemic steroid medication were
excluded from the study. The study protocol was approved
by the Institutional Review Board at Kangnam CHA Med-
ical Center and Ewha Womans University Mokdong Hos-
pital and was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice guide-
lines. Informed written consent was obtained from all par-
ents or legal guardians following a detailed explanation of
the study.
Opsonophagocytic killing assay
The opsonic indices (OI) of the samples were determined
using the OPKA as previously described [19-23]. Target
strains TREP6A, SPEC6B, SPEC6C, and SPEC6D (express-
ing capsule types 6A, 6B, 6C, and 6D, respectively) were de-
rived from wild-type strains EF6796, BG25-9, BGO-2197,
and MNZ920, respectively, and have been described previ-
ously [19,24]. Opsonic indices were defined as the serum
dilution that kills 50% of bacteria and were determined by
linear interpolation. In this study, all sera were diluted 5-
fold before the assay due to limited amounts of sera. Be-
cause all sera were diluted 5-fold during the assay, the limit
of detection was 20. A detailed protocol is posted on a web-
site (www.vaccine.uab.edu).
Statistical analysis
The analyses of serum antibody OI were based on loga-
rithms of the OIs of all subjects. Geometric mean op-
sonic indices (GMI) were evaluated and two-sided 95%
confidence intervals were determined for each pneumo-
coccal serotype. Serum samples with OIs<20 were
assigned a value of 10 for analysis purposes. The propor-
tions of subjects achieving anti-pneumococcal OI ≥20
were determined. Reverse cumulative distribution curves
were used to display percentages of children that
achieved different OI to each of the 4 pneumococcal se-
rotypes, 6A, 6B, 6C, and 6D.
Results
Characteristics of the subjects
A total of 59 subjects were included in the study. There
were 18 subjects, 21 subjects, and 20 subjects in the
booster, primary, and control group, respectively. The
mean age of subjects in the booster group was 18.8
months (range 16–23 months) with a mean interval be-
tween last vaccination and sampling of 3.3 months
(range 1–7 months). The primary group consisted of
subjects with a mean age of 13.9 months (range 12–16
months) and the mean interval between the last vaccin-
ation and sampling was 7.2 months (range 4–9 months).
The subjects in the control group were of a mean age of
14.5 months (range 12–16 months).
Immune response to serogroup 6
The GMI for each serotype in serogroup 6 for each group
of subjects is shown in Table 1. GMI of the booster group
was higher compared with the primary and control groups
for all 4 serotypes tested (Figure 1). When comparing the
Table 1 Geometric mean indices of serogroup 6 in
response to PCV7 vaccine according to vaccination status
Booster (N=18) Primary (N=21) Control (N=20)
6B GMI 5,948 123*,† 19*
95% CI (2,969–11,917) (55–263) (9–47)
6A GMI 2,065 29* 23*
95% CI (971–4,395) (12–67) (9–68)
6C GMI 808 30* 13
95% CI (224–2,913) (12–63) (8–24)
6D GMI 2,323 207* 79*
95% CI (683–7,988) (57–357) (21–476)
*P<0.05 compared with booster, †P<0.05 compared with control.
PCV7; 7-valent pneumococcal conjugate vaccine, N; number, GMI; geometric
mean index, CI; confidence interval.
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primary and control groups, GMI was higher for serotype
6B (p<0.05) in the primary group, however there was no
difference between these groups for serotype 6A, 6C, and
6D.
In the control group, 5-30% of the subjects had an
OI > = 20, depending on serotype (Figure 2 and data not
shown). In subjects who had previously been vaccinated
with PCV7 as a primary series, and have not yet received
the booster dose, 81% of the subjects had an OI ≥ 20 for se-
rotypes 6B and 6D. However in the same subjects, only
29% had an OI ≥ 20 for serotypes 6A and 6C. After a
booster dose, all subjects had OIs ≥ 20 for serotype 6B and
6A, while 89% and 78% had OIs ≥ 20 for serotypes 6D 6C,
respectively.
Discussion
Our study shows that PCV7 can elicit high levels of anti-
bodies cross-reacting with serotypes 6A, 6C, and 6D in
children 12–23 months of age. For serotype 6D, opsonic
activity was demonstrable in 81% of the primary group
and 89% of the booster group in these children. These
high antibody responses are comparable with that of
serotype 6B and actually higher than those for serotypes
6A and 6C. This finding is consistent with the paucity of
6D isolates found in the US, where PCV7 is used exten-
sively. In contrast, 6D isolates are relatively more preva-
lent in Korea. Although there are no nationwide studies
in Korea, according to a study of isolates collected from
























Figure 1 Geometric mean opsonic indices of serogroup 6 in response to PCV7 according to vaccination status. *P<0.05, Booster
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Figure 2 Reverse cumulative distribution curves of opsonic indices for serotypes 6B and 6D in booster, primary and control groups.
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be serotype 6D [17]. A second study of isolates collected
from 1997–2009 seemed to show an increase in 6D iso-
lates in recent years [25]. However these studies were
done on various populations of different ages. Therefore,
we cannot directly determine the effect of PCV7 on
serotype 6D. Further studies are needed to determine
the effect of PCV7 on the epidemiology of 6D. If an in-
crease in serotype 6D prevalence is real, it would be in-
teresting to assess the OPA activity against 6D using
isolates from Korea as target strains, to verify the high
cross-protection immune response that was detected in
this study.
In this study, 29% of the subjects in the primary group
had a detectable OI for serotype 6C. This is consistent
with the results of a previous study which found a sero-
positivity rate of 39% in infants following a 3-dose pri-
mary series (unpublished data). However, in the current
study, 78% of subjects had a detectable OI for 6C in the
booster group. Thus, the booster dose seems to signifi-
cantly enhance cross-protection against 6C.
The seropositivity rate for serotype 6C in the primary
group was relatively low compared with serotype 6D
(29% vs 81%). This finding supports the epidemiologic
phenomenon seen in 2004–2008 where an increase in
invasive pneumococcal diseases due to serotype 6C was
seen during a vaccine shortage [26]. Due to this vaccine
shortage, many children were not able to receive a
booster vaccination in 2004. With the absence of the
booster dose, cross-protection was not sufficient for vac-
cine related serotypes [27,28].
The results of this study emphasize the importance of
a booster dose for better protection of disease caused by
both vaccine serotypes and vaccine-related serotypes.
Compared to the control group which had no history of
PCV7 vaccination, the immune responses to all
serogroup 6 members were higher in primary group and
highest in booster group. Infants are restricted in their
ability to make diverse antibody variable regions and
may produce antibodies with low avidity to cross-
reactive serotypes [29]. However, it is known that mul-
tiple immunizations improve antibody maturation
through somatic mutation resulting in high affinity anti-
body [30,31]. Our results of the cross-protective immune
response according to vaccination dosages support this
finding.
There are limitations in this study. OPKA threshold for
protection is identified as OI ≥ 8. Although there is contro-
versy as to whether it is appropriate to apply a consistent
value for all serotypes, Henckaerts et al. reported in a
validation study of the OPKA, that OPKA sero-positivity
(OI ≥ 8) correlated well with IPD effectiveness [32]. Since
the threshold for OPKA was an OI ≥ 20 in this study, the
results may be rather underestimated. Also, there were dif-
ferences in age groups, where the mean age of children in
the booster group was higher than the primary or control
groups. Although none of the infants in the study had doc-
umented history of pneumococcal disease, this could have
an effect on the antibody titers between groups, related to
increase in natural exposure to pneumococcus with in-
crease in age.
Compared to published data of the US, European, or
Taiwanese infants, Korean infants had higher post-
vaccination antibody titer to all serotypes in PCV7 [33].
Therefore further studies are needed in different popula-
tion or ethnic groups. Moreover, this study is based on
the immune response of PCV7. Recently conjugate vac-
cines containing more serotypes and different conjugate
proteins have been introduced into the market [34,35].
The results of this study cannot be directly applied to
these new vaccines, and further study is needed for dif-
ferent vaccine formulations. However PCV7 is still used
in many countries. In this regard, the immune responses
of PCV7 are of importance.
Conclusion
We found that in subjects aged 12–23 months, an im-
mune response is elicited after a primary series of immu-
nizations with PCV7 for serotypes 6B and 6D and a
booster dose enhances cross reactive antibody levels
against serotypes 6A, 6C, and 6D.
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